Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using theemail support widget if the problem persists.
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | No | No |
| Is net profit margin increasing? | Yes | Yes |
| Is asset turnover increasing? | Yes | No |
| Is equity multiplier increasing? | Yes | Yes |
| Competitors Used |
|---|
| BeiGene, Ltd. |
| Keymed Biosciences Inc. |
| JW (Cayman) Therapeutics Co. Ltd |
| Staidson (Beijing) BioPharmaceuticals Co., Ltd. |
| Shanghai Kehua Bio-Engineering Co.,Ltd |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| 6,160 | 2,162 | 2,126 | 300,204 | 2,022 | CSPH.F | |||
| Return On Equity | ||||||||
| Latest Twelve Months | -19% | -19% | -41% | -15% | -8% | -22% | ||
| Fiscal Year - 1 | -22% | -11% | -38% | -34% | 22% | -81% | ||
| Fiscal Year - 2 | -38% | -9% | -33% | -14% | 24% | -109% | ||
| Fiscal Year - 3 | -29% | -304% | -23% | -9% | 25% | -92% | ||
| Fiscal Year - 4 | -67% | NA | NA | -8% | 9% | -45% | ||
| Fiscal Year - 5 | -70% | NA | 101% | 1% | 10% | NA | ||
| Average | -41% | -86% | -7% | -13% | 14% | -70% | ||
| Median | -34% | -15% | -33% | -11% | 16% | -81% | ||
| Benchmarks | Ticker | |||||||
| BeiGene, Ltd. | SEHK:6160 | |||||||
| Keymed Biosciences Inc. | SEHK:2162 | |||||||
| JW (Cayman) Therapeutics Co. Ltd | SEHK:2126 | |||||||
| Staidson (Beijing) BioPharmaceuticals Co., Ltd. | SZSE:300204 | |||||||
| Shanghai Kehua Bio-Engineering Co.,Ltd | SZSE:002022 | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | Nov-16 | Dec-05 | Oct-05 | Dec-21 | Jul-05 | CSPH.F | ||
| Latest Fiscal Year | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-23 | Dec-24 | ||
| LTM Period | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Sep-24 | Dec-24 | ||
| Revenues | ||||||||
| Latest Twelve Months | 3,810 | 428 | 158 | 325 | 1,874 | 407 | ||
| Fiscal Year | 3,810 | 428 | 158 | 325 | 2,428 | 407 | ||
| Fiscal Year - 1 | 2,459 | 354 | 174 | 364 | 6,970 | 464 | ||
| Fiscal Year - 2 | 1,416 | 100 | 146 | 549 | 4,854 | 481 | ||
| Fiscal Year - 3 | 1,176 | 110 | 31 | 584 | 4,155 | 244 | ||
| Fiscal Year - 4 | 309 | NA | NA | 425 | 2,414 | 1,039 | ||
| Fiscal Year - 5 | 428 | NA | 5 | 661 | 1,990 | NA | ||
| Net Income | ||||||||
| Latest Twelve Months | (645) | (515) | (591) | (145) | (336) | (91) | ||
| Fiscal Year | (645) | (515) | (591) | (145) | (234) | (91) | ||
| Fiscal Year - 1 | (882) | (359) | (768) | (399) | 972 | (367) | ||
| Fiscal Year - 2 | (2,004) | (308) | (846) | (197) | 850 | (903) | ||
| Fiscal Year - 3 | (1,458) | (3,887) | (702) | (137) | 675 | (1,920) | ||
| Fiscal Year - 4 | (1,625) | (819) | (1,664) | (133) | 202 | (1,221) | ||
| Fiscal Year - 5 | (949) | (168) | (633) | 27 | 208 | (2,069) | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 5,805 | 3,883 | 2,146 | 1,332 | 7,038 | 1,662 | ||
| Latest Fiscal Quarter | 5,921 | 3,767 | 1,680 | 1,150 | 5,941 | 1,393 | ||
| Fiscal Year | 5,921 | 3,767 | 1,680 | 1,150 | 6,808 | 1,393 | ||
| Fiscal Year - 1 | 5,805 | 3,883 | 2,146 | 1,332 | 8,819 | 1,662 | ||
| Fiscal Year - 2 | 6,379 | 3,932 | 2,791 | 1,669 | 6,955 | 1,638 | ||
| Fiscal Year - 3 | 8,536 | 3,934 | 3,117 | 1,827 | 5,977 | 2,271 | ||
| Fiscal Year - 4 | 5,601 | 530 | 3,779 | 1,856 | 3,705 | 3,763 | ||
| Fiscal Year - 5 | 1,612 | 659 | 669 | 1,862 | 3,504 | 2,951 | ||
| Fiscal Year - 6 | 2,250 | NA | 341 | 2,772 | 2,716 | 1,632 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 3,537 | 2,986 | 1,684 | 1,021 | 4,399 | 457 | ||
| Latest Fiscal Quarter | 3,332 | 2,475 | 1,169 | 929 | 3,925 | 364 | ||
| Fiscal Year | 3,332 | 2,475 | 1,169 | 929 | 4,172 | 364 | ||
| Fiscal Year - 1 | 3,537 | 2,986 | 1,684 | 1,021 | 4,816 | 457 | ||
| Fiscal Year - 2 | 4,383 | 3,340 | 2,354 | 1,354 | 3,872 | 449 | ||
| Fiscal Year - 3 | 6,133 | 3,651 | 2,791 | 1,551 | 3,141 | 1,207 | ||
| Fiscal Year - 4 | 3,869 | (1,095) | 3,430 | 1,588 | 2,357 | 2,954 | ||
| Fiscal Year - 5 | 962 | (276) | (942) | 1,635 | 2,177 | 2,482 | ||
| Fiscal Year - 6 | 1,739 | NA | (313) | 2,458 | 1,997 | 515 | ||